...
首页> 外文期刊>OncoTargets and therapy >Biomarker and competing endogenous RNA potential of tumor-specific long noncoding RNA in chromophobe renal cell carcinoma
【24h】

Biomarker and competing endogenous RNA potential of tumor-specific long noncoding RNA in chromophobe renal cell carcinoma

机译:肿瘤特异性长非编码RNA在发色肾细胞癌中的生物标志物和竞争性内源RNA潜能

获取原文
           

摘要

Background: Accumulating evidence suggests long noncoding RNAs (lncRNAs) play important roles in the initiation and progression of cancers. However, their functions in chromophobe renal cell carcinoma (chRCC) are not fully understood. Methods: We analyzed the expression profiles of lncRNA, microRNA, and protein-coding RNA, along with the clinical information of 59 primary chRCC patients collected from The Cancer Genome Atlas database to identify lncRNA biomarkers for prognosis. We also constructed an lncRNA–microRNA–mRNA coexpression network (competitive endogenous RNAs network) by bioinformational approach. Results: One hundred and forty-two lncRNAs were found to be differentially expressed between the cancer and normal tissues (fold change ≥1.5, P <0.001). Among them, 12 lncRNAs were also differentially expressed with the corresponding clinical characteristics (fold change ≥1.5, P <0.01). Besides, 7 lncRNAs (COL18A1-AS, BRE-AS1, SNHG7, TMEM51-AS1, C21orf62-AS1, LINC00336, and LINC00882) were identified to be significantly correlated with overall survival (log-rank P <0.05). A competitive endogenous RNA network in chRCC containing 16 lncRNAs, 18 miRNAs, and 168 protein-coding RNAs was constructed. Conclusion: Our results identified specific lncRNAs associated with chRCC progression and prognosis, and presented competing endogenous RNA potential of lncRNAs in the tumor.
机译:背景:越来越多的证据表明,长的非编码RNA(lncRNA)在癌症的发生和发展中起着重要的作用。但是,它们在发色性肾细胞癌(chRCC)中的功能尚未完全了解。方法:我们分析了lncRNA,microRNA和蛋白质编码RNA的表达谱,以及从The Cancer Genome Atlas数据库收集的59例原发性chRCC患者的临床信息,以鉴定可预测预后的lncRNA生物标志物。我们还通过生物信息学方法构建了lncRNA–microRNA–mRNA共表达网络(竞争性内源性RNA网络)。结果:发现一百四十二个lncRNA在癌组织和正常组织之间差异表达(倍数≥1.5,P <0.001)。其中12个lncRNAs也有差异表达,并具有相应的临床特征(倍数变化≥1.5,P <0.01)。此外,还鉴定出7种lncRNA(COL18A1-AS,BRE-AS1,SNHG7,TMEM51-AS1,C21orf62-AS1,LINC00336和LINC00882)与总体存活率显着相关(对数秩P <0.05)。在chRCC中构建了竞争性内源性RNA网络,其中包含16个lncRNA,18个miRNA和168个蛋白质编码RNA。结论:我们的结果鉴定了与chRCC进展和预后相关的特定lncRNA,并显示了lncRNA在肿瘤中的竞争性内源RNA潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号